Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. (ARMP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ARMP · as of Sep 30, 2025
Ownership Breakdown
28
Institutional Holders
▼ 1 vs Q2
$2.27M
Total Inst. Value
▲ $875,414 vs Q2
36.71M
Shares Outstanding
freeFloat 30.84%
759,749
13F Shares Held
▲ 24,505 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ARMP largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 297.0K | 82.07% | 82.07% | $885.17M | Nov 7, 2025 | ▲ 37.0K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 104.5K | 28.89% | 28.89% | $311.64M | Nov 12, 2025 | — held |
EDGEWOOD MANAGEMENT LLC biological products, (no diagnostic substances) | 100.0K | 27.63% | 27.63% | $298.00M | Nov 12, 2025 | — held |
BRIDGEWAY CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 44.7K | 12.35% | 12.35% | $133.15M | Nov 14, 2025 | — held |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 41.3K | 11.41% | 11.41% | $123.06M | Nov 13, 2025 | ▲ 2.4K |
STATE STREET CORP biological products, (no diagnostic substances) | 40.3K | 11.13% | 11.13% | $120.09M | Nov 14, 2025 | — held |
SEACREST WEALTH MANAGEMENT, LLC biological products, (no diagnostic substances) | 35.0K | 9.66% | 9.66% | $112.55M | Nov 13, 2025 | — held |
GSB WEALTH MANAGEMENT, LLC biological products, (no diagnostic substances) | 30.0K | 8.29% | 8.29% | $89.40M | Oct 21, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 26.7K | 7.37% | 7.37% | $79.46M | Nov 12, 2025 | ▲ 748 |
NORTHERN TRUST CORP biological products, (no diagnostic substances) | 19.3K | 5.32% | 5.32% | $57.43M | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
4
Increased
+40.2K shares2
New Positions
first time holders3
Decreased
−1.6K shares3
Sold Out
fully exitedNet shares change (top 50)
+38.6K
+40.2K / −1.6K
Net new holders
+0
2 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ARMP insider trading · insider activity
Source: SEC Form 4
9
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Gilmer Daniel B. director | Apr 24, 2026 | Award | 51,280 | $12.92 | $662.5K | 51.3K | Form 4 ↗ |
Kyme Pierre Chief Business Officer | Mar 14, 2026 | Tax Withhold | 1,030 | $10.54 | $10.9K | 9.5K | Form 4 ↗ |
Birx Deborah Chief Executive Officer | Mar 14, 2026 | Tax Withhold | 4,919 | $10.54 | $51.8K | 212.5K | Form 4 ↗ |
Kramer Robin director | Mar 9, 2026 | Award | 25,640 | $11.61 | $297.7K | 25.6K | Form 4 ↗ |
Kyme Pierre Chief Business Officer | Mar 9, 2026 | Award | 183,142 | $11.61 | $2.13M | 183.1K | Form 4 ↗ |
House David Duane SVP, Finance, and PFO | Mar 9, 2026 | Award | 109,885 | $11.61 | $1.28M | 109.9K | Form 4 ↗ |
PATTI JOSEPH M director | Mar 9, 2026 | Award | 25,640 | $11.61 | $297.7K | 25.6K | Form 4 ↗ |
Peterson Todd C. director | Mar 9, 2026 | Award | 25,640 | $11.61 | $297.7K | 25.6K | Form 4 ↗ |
Odysseas Kostas D director | Mar 9, 2026 | Award | 25,640 | $11.61 | $297.7K | 25.6K | Form 4 ↗ |
Birx Deborah Chief Executive Officer | Mar 9, 2026 | Award | 421,226 | $11.61 | $4.89M | 421.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Armata Pharmaceuticals, Inc. (ARMP) is primarily owned by institutional investors, who hold approximately 2.1% of total shares outstanding. Company insiders own approximately 69.16%, while retail and public investors account for the remaining 28.77%.
The largest institutional shareholder of Armata Pharmaceuticals, Inc. is VANGUARD GROUP INC, holding approximately 297,038 shares — equal to 82.07% of outstanding shares — as of September 30, 2025.
A total of 28 institutional investors currently hold ARMP stock, with a combined institutional value of approximately $2,272,532 as of the most recent 13F filing period.
Frequently asked questions
ARMP ownershipArmata Pharmaceuticals, Inc. (ARMP) is primarily owned by institutional investors, who hold approximately 2.1% of shares. The largest shareholder is VANGUARD GROUP INC with a 82.07% stake. Company insiders hold 69.16%. Data sourced from SEC Form 13F as of September 30, 2025.